## **Psychiatry Advisor**

Home » Topics » General Psychiatry

April 1, 2020

# **Infrared Laser Treatment of TBI, PTSD,** and Depression: An Expert Perspective



Theodore Henderson, MD, PhD











Disclosure: Dr Henderson is the president and principal owner of The Synaptic Space, a neuroimaging consulting firm, and owner of Neuro-Luminance Corporation. Please see the listed studies for a full list of disclosures.

During the last 20 years, a large body of research has accumulated on the beneficial effects of infrared light in the range of 600 to 1000 nm. Infrared light can activate mitochondria, which in turn stimulate second messenger systems, DNA transcription, and growth factors. 1,2 As a result, new synapses are formed, circuits regrow, and pluripotent stem cells differentiate into neurons.



When it comes to infrared light treatment, it is all a matter of getting there: the infrared light must be able to penetrate all the overlying tissue to reach the brain.

Animal studies have shown that infrared photobiomodulation (PBM) may reduce the size and severity of brain injury and stroke, as well as diminish damage and physiological symptoms in depression, posttraumatic stress disorder (PTSD), Parkinson disease, and Alzheimer disease. 1,3-6 Michael Hamblin, PhD. from the Wellman Center for Photomedicine at Massachusetts General Hospital in Boston, a leader in the field, describes PBM as "the use of red or near-infrared light to stimulate, heal, regenerate, and protect tissue that has either been injured, is degenerating, or else is at risk of dying."1

Advertisemen

#### Today's top picks on the Haymarket Medical Network

Patterns in Olfactory Injury Among Patients Who Died From COVID-19

Suicidal Symptoms Persist After Remission in Patients With Major Depression

Nearly 1 in 3 People With Depression Report Owning a Gun

CONTINUE READING

Generally in medicine we shy away from the word "heal" when referring to the brain, and "regenerate" stirs vague recollections of *Frankenstein*. Nevertheless, early findings in mouse models of brain injury and disease have spawned a different sort of monster in the commercial world. The internet is now loaded with companies offering infrared LED helmets or pads for the treatment of traumatic brain injury (TBI) and other brain disorders, often based on exaggerated claims about "healing" the brain. Exorbitant prices in the thousands of dollars are charged for a device that can be made for less than \$30. As a result, the public is misled and the potential scientific benefits of infrared light are sullied.

It is time to separate fact from fiction. Yes, infrared light can induce the cellular events described here, reduce the size of stroke injury or TBI in mouse models, and protect neurons from neurotoxins. But is treating a human with a 0.5-W LED the same as treating a mouse? Certainly not! When it comes to infrared light treatment, it is all a matter of getting there: the infrared light must be able to penetrate all the overlying tissue to reach the brain.

#### Can Infrared Light Reach the Brain?

Can 0.5-W LEDs penetrate human scalp and skull to reach the brain? The answer is "No." My colleague, Larry Morries, DC, and I showed that these LEDs did not even penetrate 2 mm of human skin. In contrast, our laser device, which emits infrared light in the range of 10 to 15 W, was able to effectively penetrate human tissue. We found that 33% of our 10-W infrared laser energy penetrated 2 mm of human skin and delivered from 1.2% to 2.4% of the energy from our device 3 cm into the brain. These data were replicated in a study by Juanita Anders, PhD, and colleagues at the Uniformed Services University of Health Sciences.

The human scalp and skull provide a significant barrier. Infrared light energy needs to be in the range of 0.9 to  $15 \text{ J/cm}^2$  at the target tissue to activate mitochondria and other cellular events.  $^{2\cdot3.8\cdot9}$  Even if a  $0.5\cdot$  W LED only had to penetrate the skull to reach the surface of the brain, it could only deliver  $0.0064 \text{ J/cm}^2$ , or 1/140th of the minimum energy necessary to induce PBM.  $^{10}$  No energy would be expected to reach the depths of the brain needed to treat stroke, Parkinson disease, Alzheimer disease, or many brain injuries. Although more than 40% of the incident light from a light source may penetrate mouse skull, only 4.2% penetrates human skull.  $^{8,10}$ 

There is a hairier problem facing LED devices: human hair blocks infrared light. More than 98% of infrared light can be blocked by 2 mm of hair (ie, 9.764 W of a 10-W beam of 810 nm infrared light is

absorbed by human hair).  $^{11}$  If 98% of the energy from a 0.5-W LED is absorbed by hair, 80% to 90% is absorbed by 2 mm of skin, and 96% of incident energy is attenuated by skull, then claims of neurophysiological benefits of LED-based devices become highly questionable.

Another misconception propagated by companies selling LED-based devices is that multiple LEDs somehow increase light penetration, even though each LED projects light on its own path. For example, 100 0.5-W LEDs do not generate 50 W on the brain, they generate 0.5 W on 100 spots. <sup>11</sup> The argument that light scattering in the brain provides the cumulative value of multiple LEDs also falls apart if nothing can get through the overlying tissues.

Given that a small percentage (<1%) of incident infrared light gets through human scalp and skull, we must question the results of human trials of LEDs. Studies demonstrated small yet almost insignificant positive effects, and the benefits are generally transient. <sup>12</sup> In contrast, our protocol yields persistent and robust clinical changes in patients with TBI, PTSD, and depression.

#### Treating TBI, PTSD, and Depression with Infrared Light

Our patented multi-Watt\_Neuro-Luminance approach involves transcranial infrared laser treatment (NILT), and in 2015 we published an initial open-label trial of 10 subjects with mild to moderate TBI. After a course of 10 NILT treatments (20 treatments in a subset of 4 patients), all patients experienced significant clinical improvement of symptoms, including headaches, cognitive problems, sleep disturbances, irritability, and depression. In telephone interviews every 6 months after treatment, patients report sustained improvements. 12




Figure 1. Clinical improvement of symptoms after multi-Watt NILT. Red bars, percentages of patients with symptoms before treatment; green bars, percentages of patients with symptoms after treatment.




Figure 2. Pre- and posttreatment SPECT scans in patients with TBI after a fall from a truck at freeway speed. Areas of decreased perfusion (function) in green, light blue, and dark blue show improvement after multi-Watt NILT. Color scale based on comparison to a normative database (Segami Corp) in which areas of grey are within 2 standard deviations (SD) of the mean cerebral blood flow of the normative database. Green, 2 to 3 SD below mean; light blue, 3 to 4 SD below mean; dark blue, 4 to 5 SD below mean; dark blue, 4 to 5 SD below mean; cark blue, 4 to 5 SD below mean; dark blue, 4 to 5 SD below mean; dark blue, 4 to 5 SD below mean; dark blue, 4 to 5 SD above mean.

An open-label clinical trial (n=39) of multi-Watt <u>Neuro-Luminance</u> demonstrated effectiveness for depression.<sup>4</sup> Overall, 92% of patients responded and 82% remitted, which is notably better than the response rate for oral antidepressants. Patients saw benefits within 4 treatments, and some achieved <u>resolution of depressive symptoms</u> within 8 treatments. In follow-up telephone interviews, patients report sustained improvements. Similarly, in our unpublished data, using a protocol of 20 treatments, each lasting 24 minutes, over the course of 9 weeks, 20 patients with <u>PTSD</u> treated with multi-Watt NILT experienced reduced hyperarousal, anxiety, sleep disturbance, and nightmares.

### **LED Photobiomodulation in Comparison**

Naeser and colleagues  $^{15}$  treated 2 patients with TBI daily for approximately 1 hour by applying 3 separate LED cluster heads (2 head; 1 foot). The first patient, who was 7 years post-TBI and had significant postconcussive symptoms, received weekly treatments over the course of 7 months and then daily treatments at home for more than 6 years. The patient experienced transient benefits, and if treatment was stopped, symptoms returned within 2 weeks.  $^{15}$  The second patient received daily treatments, and in 4 months, most symptoms improved, allowing her to return to work. This patient also noted that symptoms returned if treatments were stopped for more than 1 week.  $^{15}$ 

In an open-label study,  $^{16}$  11 patients with TBI and persistent cognitive dysfunction were treated for 18 sessions, each lasting 20 minutes, over the course of 6 weeks. At follow-up, there had been a significant effect on attention, inhibition, verbal learning and memory, and long-delay free recall.  $^{16}$  The LED treatment led to mild improvement in 3 of 5 cases of depression.

In 12 patients with TBI treated with 220 0.5-W LEDs for 18 sessions, each lasting 20 minutes, over the course of 6 weeks, there was significant improvement in psychological testing results (P = .45). <sup>17</sup> However, the study did not correct for multiple comparisons, instead using parallel paired t-tests, which could exaggerate findings. <sup>18</sup> PTSD has received considerably less attention. <sup>19,20</sup>

Cassano and colleagues  $^{21}$  described a 5-W laser treatment of 4 patients with depression. In a double-blind, sham-controlled extension of their initial findings, subjects in the treatment group received 16 treatments, each lasting 30 minutes, over the course of 8 weeks.  $^{22}$  In 13 completers, Hamilton-D-17

scores separated the treatment group from sham controls (mean score,  $-15.7\pm4.41$  vs  $-6.1\pm7.86$ ; P=.031). In contrast, in our open-label trial of a 13-W laser, the mean Hamilton-D-17 score decreased from baseline (mean score,  $21.48\pm5.24$  to  $6.0\pm5.12$ ;  $P=6.45\times10^{-13}$ ). <sup>23</sup>

 $\textbf{Table}. Case \ series, open-label, and \ double-blind \ studies \ of \ infrared \ light \ the rapy for \ TBI, \ PTSD, \ and \ depression$ 

Condition	Modality	Treatment	Persistence	P value	Reference
ТВІ	LED	Daily 1 hour treatments for 7 months	None: symptoms returned after treatment stopped	Case series	15
ТВІ	LED	Daily 1 hour treatments for 6 weeks	None: symptoms returned after treatment stopped	Case series	16
ТВІ	LED	18 treatments over the course of 6 weeks, 20 minutes each	Not reported	P = .045, not corrected for multiple measures	17
ТВІ	13-W laser	20 treatments over the course of 9 weeks, 20 minutes each	Persistent to at least 7 years	Case series	13
PTSD	LED	18-20 treatments over the course of 6 weeks, 110 minutes each	None	Not provided	Naeser, unpublished data
PTSD	13-W Laser	20 treatments over the course of 9 weeks, 20 minutes each	Persistent	Preliminary analysis,P =.0000067	Henderson and Morries, unpublished data
Depression	5-W Laser	16 treatments over the course of 8 weeks, 30 minutes each	None	P=.031	22
Depression	13-W Laser	20 treatments over the course of 9 weeks, 20 minutes each	Persistent to at least 5 years	P=6.45×10 <sup>-13</sup>	23

### Alternative Explanation for Clinical Response to LED Brain Treatments

Researchers, along with the human PBM field, need to reconsider the potential mechanisms underlying the meager improvements derived from LED-based devices. The light from LED devices may not

penetrate beyond the skin, but could induce central nervous system benefits via a remote or systemic effect in irradiated skin, dubbed remote photobiomodulation.<sup>24</sup>

Infrared irradiation can have remote or indirect effects on tissue that has not been irradiated. For example, Braverman and colleagues  $^{25}$  demonstrated this indirect effect by creating matching skin lesions on the left and right dorsum of a rabbit, treating 1 side with infrared light. Both lesions showed accelerated healing relative to nonirradiated controls. Rochkind and colleagues  $^{26}$  demonstrated that remote PBM could occur in the peripheral nervous system and the central nervous system. After bilateral sciatic nerve crush, 1 side was irradiated with infrared light and the other side was not. Nerves on both sides showed enhanced recovery of function, and the number of anterior horn motor neurons was greater on both sides compared with nonirradiated controls.

Ganeshan and colleagues<sup>27</sup> irradiated the dorsum and hind limbs of a rat with infrared light (670 nm) before injection of a neurotoxin (MPTP) and demonstrated reduced loss of dopaminergic neurons in rodents treated with indirect PBM to the skin compared with untreated controls. Given the overwhelming evidence that low-power LEDs do not penetrate the brain, it is more likely that the benefits of LED-based devices result from an effect mediated by the skin, where most, if not all, of the infrared energy is absorbed. In other words, LED-based devices may be working by remote PBM.

#### Conclusions

The excitement about the potential of infrared light therapy is not merely that it does not involve taking a pill. There is considerable enthusiasm about its potential to treat conditions such as TBI, dementia, and Parkinson disease. In our excitement, we must not overlook the unique physical limitations of light. Similarly, we must not imbue infrared light with magical powers. Infrared light can only work if it reaches target tissue.

Thus, a sharp divide can be drawn between LED-based treatment technologies, which offer minimal results and may not even reach the brain, and multi-Watt technologies that demonstrably reach the brain and offer lasting clinical benefit. Potentially, infrared light may prove to be effective for numerous neuropsychiatric conditions. However, for infrared light to work on the brain, it must be able to reach the brain.

#### References

- 1. Hamblin MR. <u>Shining light on the head: Photobiomodulation for brain disorders</u>. *BBA Clin*. 2016;6:113-124.
- 2. Henderson TA, Morries, LD. <u>Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain?</u> *Neuropsychiatr Dis Treat.* 2015;11:2191-2208.
- 3. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. <u>The nuts and bolts of low-level laser (light) therapy</u>. *Ann Biomed Eng.* 2012;40(2):516-533.
- 4. Henderson TA, Morries LD. <u>Multi-Watt near-infrared phototherapy for the treatment of comorbid depression: an open-label single-arm study</u>. *Front Psychiatry*. 2017;8:187.
- 5. Johnstone DM, Moro C, Stone J, Benabid AL, Mitrofanis J. <u>Turning on lights to stop neurodegeneration:</u> the potential of near infrared light therapy in Alzheimer's and Parkinson's disease. *Front Neurosci.* 2016;11:9:500.
- Hamblin MR. <u>Photobiomodulation for Alzheimer's disease: has the light dawned? Photonics</u>. 2019;6(3):77.
- 7. Tedford CE, DeLapp S, Jacques S, Anders J. Quantitative analysis of transcranial and intraparenchymal light penetration in human cadaver brain tissue. *Lasers Surg Med*. 2015;47(4):312-322.

- 8. Ando T, Xuan W, Xu T, et al. <u>Comparison of the apeutic effects between pulsed and continuous wave</u> 810-nm wavelength laser irradiation for traumatic brain injury in mice. *PLoS One*. 2011;6(10):e26212.
- 9. Yip KK, Lo SC, Leung MC, So SK, Tang CY, Poon DM. <u>The effect of low-energy laser irradiation on apoptotic factors following experimentally induced transient cerebral ischemia</u>. *Neuroscience*. 2011:190:301-306.
- 10. Lapchak PA, Boitano PD, Butte PV, et al. <u>Transcranial near-infrared laser transmission (NILT) profiles (800 nm)</u>; systematic comparison in four common research species. *PLoS One*. 2015;3;10(6):e0127580.
- 11. Henderson TA, Morries LD. Near-infrared photonic energy penetration principles and practice. In: Hamblin, MR and Huang YY, eds. *Photobiomodulation and the Brain: Low-level Laser (Light) Therapy in Neurology and Neuroscience*. London: Academic Press; 2019.
- 12. Morries LD, Henderson TA. Treatment of traumatic brain injury with near-infrared light. In: Hamblin, MR and Huang YY, eds. *Photobiomodulation and the Brain: Low-level Laser (Light) Therapy in Neurology and Neuroscience*. London: Academic Press; 2019.
- 13. Morries LD, Cassano P, Henderson TA. <u>Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy</u>. *Neuropsychiatr Dis Treat*. 2015;11:2159-75.
- 14. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. *Drugs.* 2011;71(1):43-64.
- 15. Naeser MA, Saltmarche A, Krengel MA, Hamblin MR, Knight JA. <u>Improved cognitive function after transcranial</u>. <u>light-emitting diode treatments in chronic, traumatic brain injury: two case reports</u>. *Photomed Laser Surg.* 2011;29(5):351-358.
- 16. Naeser MA, Zafonte R, Krengel MH, et al. <u>Significant improvements in cognitive performance post-transcranial</u>, red/near-infrared light-emitting diode treatments in chronic, mild traumatic brain injury; <u>open-protocol study</u>. *J Neurotrauma*. 2014;31(11):1008-1017.
- 17. Hipskind SG, Grover FL Jr, Fort TR, et al. <u>Pulsed transcranial red/near-infrared light therapy using light-emitting diodes improves cerebral blood flow and cognitive function in veterans with chronic traumatic brain injury: a case series. Photobiomodul Photomed Laser Surg. 2019;37(2):77-84.</u>
- 18. Henderson TA, Morries LD. <u>Infrared light cannot be doing what you think it is doing (re: DOI: 10.1089/photob.2018.4489)</u>. Photobiomodul Photomed Laser Surg. 2019;37(2):124-125.
- 19. Schiffer F, Johnston AL, Ravichandran C, et al. <u>Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety. Behav Brain Funct. 2009;5:46.</u>
- 20. <u>LED light therapy to improve cognitive & psychosocial function in TBI-PTSD veterans</u>. ClinicalTrials.gov. NCT02356861. https://clinicaltrials.gov/ct2/show/NCT02356861. Accessed February 29, 2020.
- 21. Cassano P, Cusin C, Mischoulon D, et al. <u>Near-infrared transcranial radiation for major depressive disorder: proof of concept study</u>. *Psychiatry J.* 2015;2015:352979.
- 22. Cassano P, Petrie SR, Mischoulon D, et al. <u>Transcranial photobiomodulation for the treatment of major depressive disorder. The ELATED-2 Pilot Trial.</u> *Photomed Laser Surg.* 2018;36(12):634-646.
- 23. Henderson TA, Morries LD. <u>Multi-Watt near-infrared phototherapy for the treatment of comorbid depression: an open-label single-arm study</u>. *Front Psychiatry*. 2017;8:187.

- 24. Gordon LC, Johnstone DM. <u>Remote photobiomodulation: an emerging strategy for neuroprotection</u>. Neural Regen Res. 2019;14(12):2086-2087.
- 25. Braverman B, McCarthy RJ, Ivankovich AD, Forde DE, Overfield M, Bapna MS. <u>Effect of helium-neon and infrared laser irradiation on wound healing in rabbits</u>. *Lasers Surg Med*. 1989;9(1):50-58.
- 26. Rochkind S, Rousso M, Nissan M, Villarreal M, Barr-Nea L, Rees DG. <u>Systemic effects of low-power laser irradiation on the peripheral and central nervous system, cutaneous wounds, and burns.</u> <u>Lasers Surg Med.</u> 1989;9(2):174-182.
- 27. Ganeshan V, Skladnev NV, Kim JY, Mitrofanis J, Stone J, Johnstone DM. <u>Pre-conditioning with remote photobiomodulation modulates the brain transcriptome and protects against MPTP insult in mice</u>. *Neuroscience*. 2019;400:85-97.

TOPICS:	ALZHEIN	MER'S DISEASE & D	EMENTI	A	DEMENTIA	DEPRESSIVE DISORDER
GENERAL PSYC	HIATRY	NEUROCOGNIT	TIVE	PARI	KINSON DISEAS	SE .
PTSD TRAUMA AND STRESSOR-RELATED				SS-REL	ATED DISORDE	RS
TRAUMATIC BE	AIN INJUR	Υ				

TOPICS	RESOURCES	SITE INFORMATION	OTHER HAYMARKET MEDICAL Back to Top ↑ WEBSITES		
Addiction	Drug Database	About Us	Cancer Therapy Advisor		
Alzheimer's Disease & Dementia	Clinical Charts	Advertise Contact Us	Clinical Advisor Clinical Pain Advisor		
ADHD	Psychiatry CME Courses				
Anxiety	Submissions				
Geriatric Psychiatry	Conferences		Dermatology Advisor		
Mood Disorders	Reprints/Permissions		Endocrinology Advisor		
Neurocognitive Disorders	Reprints/1 erinissions		Gastroenterology Advisor		
Neurodevelopmental Disorder			Hematology Advisor		
Personality Disorders			Infectious Disease Advisor		
PTSD trauma and stressor-related			McKnight's Senior Living		
Schizophrenia and Psychoses			Medical Bag		
Sleep-Wake Disorders			MPR		
More Topics			myCME		
Clinical Features			Neurology Advisor		
News			Oncology Nurse Advisor		
Therapies			Ophthalmology Advisor		
Opinion			Ophthalmology Advisor		

Practice Management

Optometry Advisor

Pulmonology Advisor

Rare Disease Advisor

Renal and Urology News

Rheumatology Advisor

The Cardiology Advisor

# haymarket

Copyright © 2022 Haymarket Media, Inc. All Rights Reserved

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's **Privacy Policy** and **Terms & Conditions**.